Dose Insider / Analyses / GLP-1 diarrhea

Diarrhea on a GLP-1How Common It Is, How Long It Lasts and What Helps

Updated November 20, 2026 · 18 min read · FDA labels 2026, STEP pooled analysis, NIDDK 2024

After nausea, diarrhea is the most often reported side effect on the Wegovy, Zepbound and Mounjaro labels. In the label trials it was reported by 30% of adults on Wegovy 2.4 mg, 19% to 23% on Zepbound, 12% to 17% on Mounjaro and 8.5% to 8.8% on Ozempic, against 1.9% to 16% on placebo.

3 daysthe median length of one episode of diarrhea on Wegovy 2.4 mg, similar to placebo
People reporting diarrheaLabel trials, share of participantsWEGOVY2.4 mg30%Placebo16%ZEPBOUND15 mg23%Placebo8%People reporting diarrheaLabel trials, share of participantsWEGOVY2.4 mg30%Placebo16%ZEPBOUND15 mg23%Placebo8%

One episode on Wegovy lasted a median of 3 days, similar to placebo.

On this page

Episodes are short: in the pooled Wegovy trials one lasted a median of 3 days, about the same as on placebo. The risk is the fluid it removes, which is why all four labels carry a kidney warning tied to dehydration. The U.S. government's patient guidance says to replace fluids and electrolytes first, and to talk with a doctor right away about diarrhea that lasts more than two days.1,2,5,6

How common diarrhea is on each medicine

Each label has a table of the reactions reported in its placebo-controlled trials. These are the rows for diarrhea.

MedicinePlaceboOn the drug, by weekly dose
Wegovy (semaglutide)16%2.4 mg30%
Zepbound (tirzepatide)8%5 mg19%10 mg21%15 mg23%
Mounjaro (tirzepatide)9%5 mg12%10 mg13%15 mg17%
Ozempic (semaglutide)1.9%0.5 mg8.5%1 mg8.8%

Prescribing information for Wegovy, Zepbound, Mounjaro and Ozempic, section 6.1.1,2,3,4

Diarrhea, by medicine and doseFDA labels
Medicine

The percentages count people who reported the reaction at least once, mild reports included. Compare each medicine with its own placebo group; the trials enrolled different people.

The excess over placebo is the part that can be put down to the drug: 14 points for Wegovy 2.4 mg, 11 to 15 points for Zepbound, 3 to 8 points for Mounjaro and about 7 points for Ozempic. Sixteen percent of adults on placebo injections reported diarrhea in the Wegovy trials, so a good share of the episodes during treatment would have happened anyway.

On the two tirzepatide labels the rate climbs with the dose, from 19% to 23% on Zepbound and from 12% to 17% on Mounjaro. On Ozempic the two doses are level. That is the opposite of constipation, which was no more frequent on higher doses of any of the four.2,3,4

The Zepbound label notes that its row combines two reported terms, diarrhea and frequent bowel movements.2 For teenagers, the Wegovy label reports diarrhea in 22% on the drug and 19% on placebo in its pediatric trial, a gap of three points.1

Diarrhea is one part of a larger group. Stomach and gut reactions of any kind were reported by 73% of adults on Wegovy and 47% on placebo, and by 56% on each dose of Zepbound and 30% on placebo. On Mounjaro the figures were 37.1% to 43.6% against 20.4%, and on Ozempic 32.7% to 36.4% against 15.3%.1,2,3,4 A joint advisory of four U.S. medical societies cautions against reading these rows as a contest between the drugs: the differences between semaglutide and tirzepatide may reflect the different background rates in the people each trial enrolled.7

What counts as diarrhea

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, defines diarrhea as passing loose, watery stools three or more times a day, or more often than is normal for you. It sorts it by length:6

Its other symptoms, in NIDDK's list, are an urgent need to use the bathroom, cramping or pain in the abdomen, loss of control of bowel movements and nausea. Research cited by NIDDK suggests that people in the United States have acute diarrhea about once a year, and that up to 5% have the chronic kind.6 That background is what the placebo rows measure.

Why a GLP-1 causes diarrhea

The mechanism is not settled. The nutrition advisory says that these medicines occasionally affect intestinal motility or secretions, contributing to diarrhea, and that higher doses are more likely to provoke stomach and gut symptoms.7 The authors of the pooled analysis of the Wegovy trials wrote that changes in the rate of transit through the lower gut may be responsible for constipation and diarrhea, although evidence is lacking.5

Three other routes to diarrhea during treatment have sources behind them.

When it starts and how long it lasts

The best measurement comes from a pooled analysis of three of the 68-week trials of Wegovy 2.4 mg, in which 29.7% of people on the drug and 15.9% on placebo reported diarrhea.5

The labels of the other three medicines say the same about timing without giving weeks. The Zepbound and Mounjaro labels state that the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time, and the Ozempic label that the majority occurred during dose escalation.2,3,4

My episode against the trialsWharton 2022, NIDDK

A median means half of the episodes were shorter and half were longer. The median is for Wegovy 2.4 mg; no label or paper we opened reports the length of an episode on Zepbound, Mounjaro or Ozempic. The two-day mark is NIDDK's for adults with diarrhea from any cause.

Because the drug made episodes more frequent without making each one longer, the dose calendar is the better guide to when to expect them. This one puts each label's earliest dose steps on your dates.

The dose steps on my calendarFDA labels
Medicine

    The steps are the earliest the label allows; a prescriber can hold a dose longer, and many people stay below the top dose. The calendar shows dates only and is not a dosing instruction.

    Why the labels care: dehydration and the kidneys

    A three-day episode sounds minor, and usually is. The labels take it seriously for one reason. All four carry a warning headed "Acute Kidney Injury Due to Volume Depletion". It says there have been reports after approval of acute kidney injury, in some cases requiring hemodialysis, and that the majority of the reported events occurred in patients who had stomach and gut reactions leading to dehydration, such as nausea, vomiting or diarrhea.1,2,3,4 The nutrition advisory adds that dehydration from severe nausea, vomiting or diarrhea can cause acute kidney injury with or without existing kidney disease, as well as heart palpitations, so efforts should be made to prevent it.7

    NIDDK explains the mechanism in plain terms: loose stools remove more fluid and electrolytes from the body than solid stools. It lists these symptoms of dehydration in adults:6

    NIDDK notes that serious health problems from dehydration are rare. It treats symptoms of dehydration during diarrhea as a reason to talk with a doctor right away.6

    What to drink, and what each cup replaces

    NIDDK's home treatment for acute diarrhea starts with fluids: drink plenty of water and liquids that contain electrolytes, such as broths and sports drinks. It adds oral rehydration solutions, liquids that contain glucose and electrolytes, which can be bought where medicines or baby supplies are sold. One caution applies to many readers of this page. NIDDK says that older adults, people with a weak immune system and people who have diabetes, kidney disease or other health conditions should talk with their doctor before drinking oral rehydration solutions, because specific solutions or amounts may suit them better.6

    The drinks differ more than their reputations suggest. These are the contents of one cup (8 fluid ounces) of each in the U.S. Department of Agriculture's food database.8

    One cupWater mLSodium mgPotassium mgSugars gCaffeine mg
    Water2379000
    Chicken broth244924451.10
    Electrolyte solution2412521926.10
    Sports drink228953712.80
    Coconut water233644049.60
    Tomato juice, salted2296155276.30
    Orange juice219249620.80
    Apple juice2191025023.90
    Milk, 1%21910736612.70
    Cola21971224.422
    Ginger ale22317221.70
    Coffee2365116095
    Black tea236788047

    USDA FoodData Central, SR Legacy, per 8 fl oz. The electrolyte solution is the database's entry for fluid replacement solutions of the Pedialyte type, and the sports drink is its entry for a ready-to-drink Gatorade.8

    What my drinks replaceUSDA data
    Show, per cup
    Cups I have had today

    Log what you drink and each symptom, and the app keeps the day's totals.

    Open the app

    Mint bars are the liquids NIDDK names for replacing fluids and electrolytes. Coral bars are drinks of the kinds it says can make diarrhea worse: caffeine, large amounts of simple sugars, or lactose. Each tap adds a cup, and a fourth tap removes the drink. The totals describe the drinks; they are not a target.

    Four things in the table go against habit.

    A sports drink is a weak electrolyte drink. A cup has 95 mg of sodium and 37 mg of potassium, against 252 mg and 192 mg in the electrolyte solution, and twice the sugar.

    Broth replaces sodium and little else. A cup of chicken broth has 924 mg of sodium and 45 mg of potassium.

    Ginger ale replaces almost nothing. It has 17 mg of sodium, 2 mg of potassium and 21.7 grams of sugar per cup. NIDDK lists sweetened beverages among the drinks that can make diarrhea worse.6

    Juice brings potassium with a sugar load. Orange juice has 496 mg of potassium per cup, more than any other drink here except salted tomato juice, and 20.8 grams of sugar. NIDDK names some fruit juices among the sources of the simple sugars it says to avoid during acute diarrhea.6

    What to eat and what to skip

    NIDDK does not prescribe a special diet. Its guidance is that you may not feel like eating during acute diarrhea, and that when your appetite returns you can most often go back to your normal diet, even if you still have diarrhea. It says most experts do not recommend a restricted diet or fasting, with one exception: a short list of foods and drinks that could make acute diarrhea worse.6

    The advisory written for people on GLP-1 therapy gives two more pieces of advice for diarrhea. Avoiding large or high-fat meals can be helpful, and if the diarrhea is pronounced, fiber capsules or powders provide bulk to the stool.7 Fiber is the one remedy the advisory names for both diarrhea and constipation.

    For diarrhea that keeps returning, NIDDK suggests a food journal: what you eat and drink, what symptoms you have, when they occur, and which foods and drinks make them worse.6 On a weekly injection the journal has one more column worth keeping, the day of the dose and the dose itself, since the trials show the episodes clustering around the dose steps.

    Over-the-counter medicines and probiotics

    NIDDK says that in most cases acute diarrhea can be safely treated with over-the-counter medicines such as loperamide and bismuth subsalicylate. It gives two limits. Doctors typically recommend against these medicines for people who have bloody stools or fever, which can be signs of an infection. And a person whose diarrhea gets worse or lasts more than two days while taking one should see a doctor.6 The nutrition advisory agrees that anti-diarrheal medications can provide acute relief on a GLP-1.7 Doses are on the package label and are not given here.

    Probiotics get a cooler verdict. NIDDK says researchers are still studying them, and that many doctors and professional societies do not believe the evidence supports their use in treating or preventing diarrhea. It advises talking with a doctor before using them.6

    When the cause is something else

    With a placebo rate of 8% to 16% in the weight trials, many episodes during treatment have nothing to do with the injection. NIDDK names viral gastroenteritis, food poisoning and medicine side effects as the most common causes of acute diarrhea.6 A few of its causes deserve a second look from someone on a GLP-1.

    Diarrhea that lasts for weeks is a different problem from the short episodes in the trials. NIDDK's causes of persistent and chronic diarrhea are infections, food allergies and intolerances, digestive tract problems, abdominal surgery and long-term use of medicines, and it notes that chronic diarrhea can cause malabsorption.6 None of the labels describes diarrhea of that length, and the median episode in the Wegovy trials was three days.

    Does the dose matter?

    For diarrhea it does, at least on tirzepatide. The Zepbound row rises from 19% on 5 mg to 23% on 15 mg, and the Mounjaro row from 12% to 17%.2,4 The advisory describes stomach and gut side effects in general as more likely in the first weeks of treatment and with each dose escalation, and as tending to decrease in frequency and severity once the dose is stable. It calls gradual dose escalation a way to help the body adjust over time.7

    The labels leave room to slow down. The Wegovy label says that if a patient does not tolerate a dose during escalation, the prescriber can consider delaying the next step for four weeks. The Zepbound label says to consider treatment response and tolerability when selecting the maintenance dose, and a lower maintenance dose if the current one is not tolerated.1,2 These are decisions for the prescriber.

    Few people stop treatment over it. In the Wegovy trials diarrhea ended treatment for 0.7% of adults on the drug and 0.1% on placebo. Stomach and gut reactions of every kind together ended it for the shares below.1,2,3,4

    MedicinePlaceboStopped because of a stomach or gut reaction
    Wegovy injection, adults0.7%4.3%
    Zepbound0.5%5 mg1.9%10 mg3.3%15 mg4.3%
    Mounjaro0.4%5 mg3.0%10 mg5.4%15 mg6.6%
    Ozempic0.4%0.5 mg3.1%1 mg3.8%

    Prescribing information, section 6.1.1,2,3,4

    When to call a doctor

    NIDDK's rule for diarrhea from any cause is to talk with a doctor right away about any of the following:6

    For adults it adds three more: diarrhea lasting more than two days, a high fever, and six or more loose stools per day. It also names four groups who are more likely to have complications and should keep in touch with their doctor: people who are pregnant, are over age 65, are taking antibiotics, or have a weakened immune system.6

    Two of these collide with what the trials call typical. The median episode on Wegovy was three days, which is already past NIDDK's two-day mark. The rule was written for diarrhea from any cause, and it is the cautious reading: on a medicine with a kidney warning tied to dehydration, a call on day three costs little. Vomiting is also a common reaction to these medicines, and together with diarrhea it adds to the fluid loss.

    Diarrhea, plus what?NIDDK
    Along with diarrhea I have
    Signs of dehydration
    Also true for me

    The list is NIDDK's for adults and applies to diarrhea from any cause. It cannot examine you. If something feels seriously wrong, do not wait for a page to agree.

    The labels' own warning on severe reactions gives a sense of scale. Severe stomach and gut reactions of any kind were reported in 4.1% of adults on the Wegovy injection against 0.9% on placebo, in 1.7% to 3.1% on Zepbound against 1%, in 0.4% to 1.3% on Mounjaro against 0.9%, and in 0.4% to 0.8% on Ozempic against 0%.1,2,3,4 The labels do not break out severe diarrhea.

    If you take the medicine for diabetes

    Ozempic and Mounjaro, the versions approved for type 2 diabetes, have the lower rows: 8.5% to 8.8% and 12% to 17%, against 1.9% and 9% on placebo.3,4 Two points in the guidance above apply with more force. NIDDK asks people who have diabetes or kidney disease to talk with their doctor before using oral rehydration solutions.6 And the drinks that people reach for carry sugar: 12.8 grams in a cup of sports drink, 20.8 in orange juice and 24.4 in cola, by the USDA figures.8 Broth and water carry almost none.

    Diarrhea and constipation on the same medicine

    The labels report both, diarrhea a little more often: 30% against 24% on Wegovy, 19% to 23% against 11% to 17% on Zepbound, 12% to 17% against 6% to 7% on Mounjaro, and 8.5% to 8.8% against 3.1% to 5% on Ozempic.1,2,3,4 They behave differently. An episode of diarrhea lasted a median of 3 days and one of constipation 47 days, and diarrhea rises with the dose on tirzepatide while constipation does not.5

    The two are also linked. The advisory warns that extended constipation can lead to reactive diarrhea, and the laxatives used for constipation list diarrhea among their side effects.7,9 Someone who swings between the two has a reason to bring both to the prescriber together, with dates. Our page on constipation on a GLP-1 covers the other half.

    Short answers to common questions

    Does Ozempic cause diarrhea?

    Yes. In the label trials it was reported by 8.5% on 0.5 mg and 8.8% on 1 mg, against 1.9% on placebo.

    Does Zepbound cause diarrhea?

    Yes. It was reported by 19% on 5 mg, 21% on 10 mg and 23% on 15 mg, against 8% on placebo.

    How long does diarrhea last on a GLP-1?

    The only measurement is for Wegovy 2.4 mg: a median of 3 days for one episode, similar to placebo.

    When does it start?

    Mostly while the dose is being raised. In the Wegovy trials the share of people with diarrhea peaked at about week 20 and decreased afterwards.

    Does it go away?

    It becomes less frequent after the dose steps end. On Wegovy it stayed more common than on placebo through week 68.

    What should I drink?

    NIDDK says water and liquids with electrolytes, such as broths and sports drinks, or an oral rehydration solution. People with diabetes or kidney disease should ask their doctor before using a rehydration solution.

    Can I take an anti-diarrheal medicine with a GLP-1?

    The nutrition advisory for GLP-1 therapy says anti-diarrheal medications can provide acute relief. NIDDK advises against them when there is fever or blood in the stool, and says to see a doctor if diarrhea lasts more than two days while taking one.

    Do probiotics help?

    NIDDK says many doctors and professional societies do not believe the evidence supports them for treating or preventing diarrhea.

    Is diarrhea on a GLP-1 dangerous?

    Usually not. The danger is dehydration: all four labels warn of acute kidney injury in people who lost fluid through vomiting or diarrhea.

    Is diarrhea a sign the medicine is working?

    No source here says so. In the pooled Wegovy trials, people with stomach and gut events lost only slightly more weight than people without them.

    How this page was built

    Every number was read in its source on November 20, 2026. The rates come from the current prescribing information of the four medicines. The timing and length of episodes come from a pooled analysis of the Wegovy trials, funded by the drug's maker. The home treatment, the warning signs and the causes come from four NIDDK pages last reviewed in September 2024, the advice specific to GLP-1 therapy from a joint advisory of four medical societies, and the contents of the drinks from the USDA's SR Legacy database.

    The limits are these. None of the sources tested a treatment for diarrhea specifically in people taking a GLP-1; NIDDK's guidance is for diarrhea in general, and the advisory is expert opinion. The length of an episode is known for Wegovy only. The label rates count every report regardless of severity. The drinks are single database entries, and brands differ. This page does not suggest doses of any medicine.

    Sources

    1. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 2, 5 and 6. accessdata.fda.gov
    2. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 2, 5 and 6. accessdata.fda.gov
    3. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 2, 5 and 6. accessdata.fda.gov
    4. MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 2, 5 and 6. accessdata.fda.gov
    5. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab 2022;24:94-105. doi:10.1111/dom.14551
    6. National Institute of Diabetes and Digestive and Kidney Diseases. Diarrhea: Definition and Facts; Symptoms and Causes; Treatment; Eating, Diet, and Nutrition. Last reviewed September 2024, read November 20, 2026. niddk.nih.gov
    7. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring) 2025;33:1475-1503. doi:10.1002/oby.24336
    8. U.S. Department of Agriculture, Agricultural Research Service. FoodData Central, SR Legacy (2018), read November 20, 2026: entries 173647, 174536, 169883, 173660, 174831, 170458, 169098, 173933, 170872, 174852, 174846, 171890 and 173227. fdc.nal.usda.gov
    9. Chang L, Chey WD, Imdad A, et al. American Gastroenterological Association-American College of Gastroenterology clinical practice guideline: pharmacological management of chronic idiopathic constipation. Gastroenterology 2023;164:1086-1106. doi:10.1053/j.gastro.2023.03.214

    Related analyses

    Log each dose and each symptom, and see whether the episodes follow your dose steps.

    Open Dose Insider